Redeyes view on the Q3 report. The report was weak, in our opinion, even considering the challenges ...
Redeye provides an initial take on FlexQube's Q3 report, where FlexQube reported all-time high sales...
Redeye will make forecast adjustments following Binero’s Q3 2022 report, where the revenues came in ...
Redeye retains its positive view on Fortnox despite a Q3 report coming in somewhat short of our expe...
Redeye comments on Beijer Group’s Q3 report, which continued to show strength.
Redeye comments on Stillfront’s Q3-results which came in better than expected driven by strong topli...
Redeye comments on Carasent's Q3 report, which was partly known due to preliminary numbers released ...
Redeye states Enea’s Q3 report was somewhat better than expected on top line and that profitability ...
Redeye retains its positive take on Lagercrantz following a solid Q2.
Redeye is only making some minor adjustments to our near-term forecasts following the Q3 report and ...
Redeye strengthens its positive view of Proact following a solid Q3 report in basically every aspect...
Tillväxtutsikterna inför Coors tredje kvartal ser starka ut men lönsamheten förväntas pressas kortsi...
Redeye comments on today’s news from Coala Life where the company states that it will start to repor...
Redeye is astonished by the news of Alelion’s second-largest customer significantly increasing its s...
Q3: 21% org growth and adj. EBITA +12% vs ABG System sales +22% vs ABGe, service +1% vs ABGe Cloud...
Redeye looks favorably on Beijer Group’s press release about a new financing agreement, giving the c...
Q3 results in line with ABGSCe Aims for 20% sales CAGR until 2026 inc.
Q3 result in line with pre-announced numbers US weaker in Q3; expect resumed group growth in 2023 ...
Sales -6% vs. ABGSCe Adj. EBITDA -32% vs. ABGSCe SEK 600m rights issue Q3 report Midsona’s Q3 res...
Encouraging progress on BD, litigation, and clinical front Opens for making NEX-18 superior to Vida...
